Lexicon Pharmaceuticals Receives Dec. 20, 2024 PDUFA Goal Date For Sotagliflozin Type 1 Diabetes NDA Resubmission
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals has received a PDUFA goal date of December 20, 2024, for the resubmission of its New Drug Application (NDA) for Sotagliflozin, a treatment for Type 1 diabetes.
July 16, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexicon Pharmaceuticals has received a PDUFA goal date of December 20, 2024, for the resubmission of its NDA for Sotagliflozin, a treatment for Type 1 diabetes. This regulatory milestone is crucial for the company's future prospects.
The PDUFA goal date is a significant regulatory milestone that could lead to the approval of Sotagliflozin, potentially boosting Lexicon Pharmaceuticals' market position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100